| |
Septemeber 8-11, 2025 | Philadelphia, PA Where biotech breakthroughs meet pharma scale. Dive into dynamic discussions on translational science, dealmaking, and the innovation shaping the next generation of therapies. Register now to connect and collaborate.
|
|
Today’s Big NewsJun 6, 2025 |
|
Monday, June 16, 2025 | 12pm ET / 9am PT Join a candid and informative discussion between precision medicine experts. They will share lessons learned and concrete opportunities to transform clinical trial design, execution and outcomes. Register now.
|
|
| By Kevin Dunleavy Days after FDA Commissioner Marty Makary said that the agency planned to review the safety of abortion pill mifepristone, attorneys general from four pro-abortion states have fired back, filing a petition asking the U.S. regulator to lift restrictions on the treatment. |
|
|
|
By Zoey Becker In the study, diabetes patients who took GLP-1s were twice as likely to develop neovascular age-related macular degeneration (nAMD) than those without GLP-1 exposure. |
By Emma Beavins The National Institutes of Health is seeking comment from industry on a new artificial intelligence strategy for the agency. |
By Darren Incorvaia A new paper published in Nature on June 4 shines light on how an enigmatic part of male aging—the loss of Y chromosomes—is connected with a higher risk of dying from cancer. |
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness.
|
|
By Ayla Ellison,Angus Liu,Gabrielle Masson,Zoey Becker This week on "The Top Line," the Fierce team reports from ASCO, highlighting key takeaways on clinical data, standout campaigns and buzz from the exhibit floor. |
By Gabrielle Masson As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: raising the bar for his biotech’s investigational treatment. |
By Darren Incorvaia,Zoey Becker Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, who brings to the table two decades of industry experience. Before his most recent position as Rafael Holdings’ CEO, Conkling spent over 10 years at Novartis including as commercial lead for the launch of the first ever approved CAR-T therapy, Kymriah, in 2017. |
By Angus Liu The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. AstraZeneca and Daiichi Sankyo trotted out Enhertu's detailed data in first-line breast cancer. Regeneron signed on a GLP-1/GIP candidate from Hansoh Pharma. And more. |
By Andrea Park Argenx has signed on as an early partner to a newly launched initiative from media companies NBCUniversal Local and Digital Health Networks (DHN) that plans to offer healthcare marketing in the form of video and digital storytelling content. |
By Fraiser Kansteiner Novartis has submitted a request in Delaware federal court urging the judge who oversaw a December patent litigation trial to issue a final decision and verdict on the case before July 15. If it gets its way, Novartis could block generic rival MSN from launching its Entresto copycat until late next year. |
By James Waldron Otsuka Pharmaceutical has shared data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio levels. |
By Nick Paul Taylor TegMine Therapeutics has secured certain rights to OBI Pharma’s antibody-drug conjugate technology, advancing the efforts of former Stemcentrx scientists to treat cancer by targeting carbohydrates. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," the Fierce team reports from ASCO, highlighting key takeaways on clinical data, standout campaigns and buzz from the exhibit floor. |
|
|---|
|
|
|
Tuesday, June 17, 2025 | 11am ET / 8am PT Join experts from NIBRT and Securecell AG to explore how advanced Process Analytical Technologies (PAT) are transforming bioprocessing. Register now.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
